Imagine being introduced to the world with the wrong name.
For years, people misunderstood you. They focus on the wrong features, make assumptions and miss what truly matters.
That, in many ways, has been the story of one of the most common medical conditions affecting women.
For decades, we called it Polycystic Ovary Syndrome or PCOS.
Now, after years of international debate, consultation and research, the condition has officially been renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The change was endorsed by major international organisations and published in The Lancet in 2026.
At first glance, this may appear to be little more than medical bureaucracy. A few experts sitting in a room, rearranging letters and updating guidelines.
It is much more important than that. The new name acknowledges something women have been saying for years.
The old name never told the full story. In fact, it often told the wrong story.
Many women diagnosed with PCOS never had cysts.
Many women with ovarian cysts never had PCOS.
The term created confusion among patients, families and even healthcare professionals. It implied that the condition was primarily a problem of the ovaries when, in reality, the ovaries are only one part of a much larger picture.
The new name is longer and admittedly less catchy. Yet it is far more accurate.
PMOS recognises that this is a disorder involving multiple hormone systems and important metabolic abnormalities. It affects reproduction, certainly, but it also affects weight, insulin action, cardiovascular risk, mental health, sleep, skin and long-term wellbeing.
That distinction matters because names influence how diseases are understood.
Consider heart disease. If we renamed it “Chest Pain Syndrome”, countless people would overlook the roles of cholesterol, blood pressure, smoking and diabetes.
Similarly, calling PMOS “Polycystic Ovary Syndrome” encouraged generations to think mainly about ovaries while missing the broader metabolic storm occurring beneath the surface.
As an endocrinologist, I have seen this repeatedly. A young woman presents with irregular periods. Another seeks help for unwanted facial hair. Someone else struggles with acne, weight gain or fertility concerns. Often, they have visited multiple healthcare providers before the pieces of the puzzle are finally assembled. Many leave consultations feeling frustrated. Some feel dismissed.
Others are told to lose weight without anyone adequately explaining why weight gain itself may be part of the condition.
For many patients, diagnosis brings an unexpected sense of relief. Not because they are happy to have a disorder. Because they finally have an explanation.
PMOS affects roughly one in eight women worldwide. Yet studies suggest that many cases remain undiagnosed. Some women spend years wondering why their periods are irregular, why weight seems unusually difficult to lose, or why fertility challenges have emerged.
The visible symptoms often attract the most attention.
• Facial hair.
• Acne.
• Scalp hair thinning.
• Weight gain.
• Irregular menstruation.
• Infertility.
The invisible consequences can be even more important.
Many women with PMOS have insulin resistance, a condition in which the body’s cells do not respond normally to insulin. The pancreas compensates by producing more insulin, creating a cascade of hormonal effects that contributes to weight gain, elevated testosterone levels and long-term metabolic complications.
PMOS is associated with increased risks of type 2 diabetes, fatty liver disease, sleep apnoea, hypertension and cardiovascular disease. It affects confidence, body image, relationships and mental health. Anxiety and depression occur more frequently among women living with PMOS, particularly when symptoms are severe or diagnosis is delayed.
Historically, conversations around the condition focused heavily on fertility. Fertility is undeniably important, but many women with PMOS are not trying to become pregnant. They are trying to understand why their bodies seem to be working against them.
The new name signals that women’s health should not be viewed solely through the lens of reproduction.
A woman’s health is not defined by her ovaries. Nor is PMOS.
One of the most exciting developments in recent years has been the emergence of newer therapies that target the metabolic aspects of the condition.
GLP-1 receptor agonists, originally developed for diabetes and later used for obesity management, have shown promising benefits in women with PMOS. Studies suggest improvements in weight, insulin resistance, ovulation and overall metabolic health. For some women, these medications are helping address one of the core drivers of the syndrome rather than simply treating individual symptoms.
Lifestyle interventions remain essential. Healthy nutrition, regular physical activity, adequate sleep and weight management continue to form the foundation of care.
Yet the conversation is becoming more sophisticated.
For too long, many women heard simplistic advice.
“Just lose weight.”
Few phrases have generated more frustration in endocrinology.
Weight management is important, but PMOS helps explain why achieving and maintaining weight loss can be especially challenging for some patients. Understanding the biology matters.
Compassion matters too.
The renaming of PCOS to PMOS will not instantly transform lives. It will not cure infertility. It will not eliminate insulin resistance. It will not make unwanted symptoms disappear overnight.
What it can do is improve understanding.
Good medicine begins with accurate diagnosis. Accurate diagnosis begins with accurate language.
The old name focused attention on a structure. The new name focuses attention on a syndrome. That may sound like a small distinction.
For millions of women around the world, it is anything but small. Sometimes the first step towards better care is finally calling a disease by the right name.
